A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon

The purpose of this study is to determine if Vascana, a novel topical formulation of nitroglycerin, is effective in the treatment and prevention of the symptoms associated with Raynaud's Phenomenon.

Start Date01 Jun 2009

Sponsor / Collaborator

MediQuest Therapeutics, Inc.

NCT00841594 / CompletedPhase 1

MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects

The purpose of this clinical study is to compare the pharmacokinetic profiles of a topical cream formulation of 0.9% nitroglycerin, MQX 503, and Nitroglycerin Ointment 2%, USP.

Start Date01 Feb 2009

Sponsor / Collaborator

MediQuest Therapeutics, Inc.

EUCTR2006-004346-17-GB / Not yet recruitingNot Applicable

Phase IIB Dose Response and Safety Study of Topical Formulationsof Methotrexate (MQX-5902, MQX-5904 and MQX-5906)in the Treatment of Fingernail Psoriasis - MQT Nail

Start Date19 Feb 2008

Sponsor / Collaborator

MediQuest Therapeutics, Inc.

100 Clinical Results associated with MediQuest Therapeutics, Inc.

0 Patents (Medical) associated with MediQuest Therapeutics, Inc.

Literatures (Medical) associated with MediQuest Therapeutics, Inc.

01 Jan 2009·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Structure-Activity Relationships of Antimicrobial and Lipoteichoic Acid-Sequestering Properties in Polyamine Sulfonamides

Q2 · MEDICINE

Article

Author: Burns, Mark R. ; David, Sunil A. ; Warshakoon, Hemamali J.

ABSTRACT We have recently confirmed that lipoteichoic acid (LTA), a major constituent of the gram-positive bacterial surface, is the endotoxin of gram-positive bacteria that induces proinflammatory molecules in a Toll-like receptor 2 (TLR2)-dependent manner. LTA is an anionic amphipath whose physicochemical properties are similar to those of lipopolysaccharide (LPS), which is found on the outer leaflet of the outer membranes of gram-negative organisms. Hypothesizing that compounds that sequester LPS could also bind to and inhibit LTA-induced cellular activation, we screened congeneric series of polyamine sulfonamides which we had previously shown effectively neutralized LPS both in vitro and in animal models of endotoxemia. We observed that these compounds do bind to and neutralize LTA, as reflected by the inhibition of TLR2-mediated NF-κB induction in reporter gene assays. Structure-activity studies showed a clear dependence of the acyl chain length on activity against LTA in compounds with spermine and homospermine scaffolds. We then sought to examine possible correlations between the neutralizing potency toward LTA and antimicrobial activity in Staphylococcus aureus . A linear relationship between LTA sequestration activity and antimicrobial activity for compounds with a spermine backbone was observed, while all compounds with a homospermine backbone were equally active against S. aureus , regardless of their neutralizing potency toward LTA. These results suggest that the number of protonatable charges is a key determinant of the activity toward the membranes of gram-positive bacteria. The development of resistance to membrane-active antibiotics has been relatively slower than that to conventional antibiotics, and it is possible that compounds such as the acylpolyamines may be useful clinically, provided that they have an acceptable safety profile and margin of safety. A more detailed understanding of the mechanisms of interactions of these compounds with LPS and LTA, as well as the gram-negative and -positive bacterial cell surfaces, will be instructive and should allow the rational design of analogues which combine antisepsis and antibacterial properties.

01 Nov 2001·Genes to CellsQ4 · BIOLOGY

Cell culture analysis of the regulatory frameshift event required for the expression of mammalian antizymes

Q4 · BIOLOGY

Article

Author: Jiadong Zhou ; John F. Atkins ; Michael T. Howard ; C. Lance Carlson ; Senya Matsufuji ; Raymond F. Gesteland ; Reitha S. Weeks ; Brian H. Shirts

Background Antizyme is a critical regulator of cellular polyamine levels due to its effect on polyamine transport and its ability to target ornithine decarboxylase for degradation. Antizyme expression is autoregulatory, through dependence on an unusual +1 translational frameshift mechanism that responds to polyamine levels.Results HEK293 cells were depleted of polyamines by treatment with an ornithine decarboxylase inhibitor, difluoromethylornithine (DFMO), and grown in the presence or absence of exogenous polyamines prior to the analysis of ribosomal frameshifting levels. Results obtained using an optimized dual luciferase assay system reveal a 10‐fold dynamic range of frameshifting, which correlates positively with polyamine addition. Polyamine addition to cells, which have not been pre‐treated with DFMO, also resulted in an increase in antizyme frameshifting but to a lesser degree (1.3 to 1.5‐fold). In addition, the constructs with the 3′ deletion were more responsive to stimulation by polyamine addition than those with the 5′ deletion.Conclusions The observed regulation of antizyme frameshifting demonstrates the efficiency of a polyamine homeostatic mechanism, and illustrates the utility of a quantifiable cell‐based assay for the analysis of polyamines or their analogues on translational frameshifting.

Lipophilic lysine-spermine conjugates as polyamine transport inhibitors: Effects of hydrocarbon structure and amino acid stereochemistry

Author: Weeks, Reitha S. ; Burns, Mark R. ; Graminski, Gerard F.

It has been hypothesized that one method whereby cancer cells can circumvent the ability of polyamine biosynthesis inhibitors from completely depleting their internal polyamines is via the import of these mols. from external sources.We have developed a group of polyamine analogs that potently inhibit this polyamine uptake system in a series of cancer cell lines.Modification of various nitrogen atom substituents together with the stereochem. of the amino acid portion of our earlier lead compound, L-Lys-Spm, has produced candidates with several orders of magnitude higher potency.Compounds were evaluated by their ability to inhibit the uptake of radiolabeled 3H-spermidine into MDA-MB-231 breast cancer cells.Addnl., the analogs′ ability to increase the growth inhibitory effects of the polyamine biosynthesis inhibitor DFMO, even in the presence of added external spermidine, was evaluated.Finally, their ability to deplete polyamine levels in these cells, when used in combination with DFMO, was measured.

100 Deals associated with MediQuest Therapeutics, Inc.

100 Translational Medicine associated with MediQuest Therapeutics, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ORI-1327	Neoplasms More	Discontinued
ORI-1313	Neoplasms More	Discontinued
ORI-1202	Breast Cancer More	Pending
MQT-1426	Neoplasms More	Pending
ORI-1426	Melanoma More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

MediQuest Therapeutics, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Dec 2024

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing